This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Minims Sodium chloride

OTC
Read time: 1 mins
Last updated: 28 Nov 2019
...
 

Summary of product characteristics


1. Name of the medicinal product

Minims Saline 0.9% w/v Eye Drops Solution


2. Qualitative and quantitative composition

A clear, colourless liquid containing Sodium Chloride Ph Eur 0.9% w/v.


3. Pharmaceutical form

Single-use, sterile eye drops.


4.1. Therapeutic indications

As a topical ocular irrigating solution.


4.2. Posology and method of administration

Adults (including the elderly) and Children:

Adequate solution should be used to irrigate the eye.


4.3. Contraindications

None.


4.4. Special warnings and precautions for use

None.


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

Not applicable.


4.7. Effects on ability to drive and use machines

None known.


4.8. Undesirable effects

None known.


4.9. Overdose

Not applicable.


5.1. Pharmacodynamic properties

Minims Saline is an isotonic solution of sodium chloride used for irrigation of the eye. There are no pharmacodynamic properties of relevance for this product.


5.2. Pharmacokinetic properties

There are no pharmacokinetic properties which are applicable for this product.


5.3. Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


6.1. List of excipients

Purified Water


6.2. Incompatibilities

None known.


6.3. Shelf life

15 months.


6.4. Special precautions for storage

Store below 25°C. Do not freeze. Protect from light.


6.5. Nature and contents of container

A sealed conical shaped container fitted with a twist and pull off cap overwrapped in an individual polypropylene/paper pouch. Each Minims unit contains approximately 0.5ml of solution.


6.6. Special precautions for disposal and other handling

Discard each unit after a single use.


7. Marketing authorisation holder

Bausch & Lomb UK Limited

Bausch & Lomb House

106 London Road

Kingston-Upon-Thames

Surrey, UK

KT2 6TN


8. Marketing authorisation number(s)

PL 03468/0081


9. Date of first authorisation/renewal of the authorisation

Date of first Authorisation: 19.5.87.


10. Date of revision of the text

January 2015

4.1 Therapeutic indications

As a topical ocular irrigating solution.

4.2 Posology and method of administration

Adults (including the elderly) and Children:

Adequate solution should be used to irrigate the eye.

4.3 Contraindications

None.

4.4 Special warnings and precautions for use

None.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Not applicable.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

None known.

Drug section

Journals
Journal
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials

Purpose: To report the durability of voretigene neparvovec-rzyl (VN) adeno-associated viral vector-based gene therapy for RPE65 mutation-associated inherited retinal dystrophy (IRD), including results of a phase 1 follow-on study at year 4 and phase 3 study at year 2.

1 mins
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).